Alnylam Shares Plunge 25% After $200 Million 2026 Sales Cut and Legal Probe
Updated
Updated · pluang.com · Aug 28
Alnylam Shares Plunge 25% After $200 Million 2026 Sales Cut and Legal Probe
2 articles · Updated · pluang.com · Aug 28
Summary
Alnylam shares sank about 25%, or $81.14 a share, after the company cut its 2026 sales outlook and disclosed a legal probe.
The forecast reduction totaled roughly $200 million and was tied to slower demand for Alnylam's transthyretin, or TTR, products.
The selloff stood out against a generally strong biotech sector, underscoring how sharply investors reacted to the weaker demand outlook and added legal overhang.
The drop leaves Alnylam facing pressure on both growth expectations and investor confidence as it navigates softer product momentum and the investigation.